Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences has completed its $2.9 billion acquisition of Soleno Therapeutics, finalizing a cash tender offer at $53.00 per share. The deal adds VYKAT XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s existing portfolio of INGREZZA and CRENESSITY.
Key figures
- Deal Value Usd
- 2900000000
- Offering Price
- 53
- Shares tendered
- 46356114
- Tender percentage
- 88.9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.